Virtual Conference
Heart 2022 Conference

Fatima Faraz

, Pakistan

Title: Efficacy of transcatheter ablation for atrial fibrillation in hypertrophic cardiomyopathy; A systematic review and meta-analysis


Background and purpose: Approximately 20-25% of the patients with hypertrophic cardiomyopathy (HCM) develop atrial fibrillation (AF) during the clinical course of the disease, and is associated with a deterioration of clinical status. Catheter Ablation (CA) of symptomatic AF is an established therapy. We conducted a systematic review and meta-analysis of the available data to evaluate the effectiveness and safety of CA for AF in patients with HCM. 

Methods: Four databases were accessed to identify studies describing outcomes of CA of AF in HCM patients after the index procedure. Data from 22 studies were included with a total of 1298 patients with a mean age ranging from 48.7 to 65 years. Data extracted were: 1) Single procedure outcome 2) Multiple procedure outcome 3) Outcomes such as Heart failure hospitalization and thromboembolic events. 

Results: Freedom from AF/AT after a single procedure at the latest follow up was reported in 426 out of 1125 patients, giving a pooled proportion of 37.9% (95% CI 33.39-42.48%, I2 = 59.3%). Multiple procedure success rate was 52% (95% CI = 45% to 58%). The rate of heart failure hospitalization after CA was 14% (95% CI= 3.8% to 30.9%). There was 4.8% occurrence of thromboembolic events post CA (95% CI= 1.9% to 9%, I2= 75.1%) 

Conclusion: Catheter ablation of AF in patients with HCM is an excellent strategy, although more repeat procedures are required to maintain the stable sinus rhythm


To be updated soon...